mitomycin has been researched along with Disease Exacerbation in 146 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It remains unclear whether people with non-muscle invasive bladder cancer (NMIBC) benefit from intravesical gemcitabine compared to other agents in the primary or recurrent setting following transurethral resection of a bladder tumor." | 9.12 | Intravesical gemcitabine for non-muscle invasive bladder cancer. ( Cleves, A; Dahm, P; Han, MA; Hwang, EC; Hwang, JE; Jung, JH; Maisch, P; Narayan, V, 2021) |
| "To report the 10-year follow-up of a study randomizing between instillations of bacillus Calmette-Guérin (BCG) and mitomycin-C (MMC) for treating high-risk and not muscle-invasive urinary bladder cancer to assess progression, the need for more aggressive treatment and survival (cancer-specific and overall), as many of the published studies comparing different treatments for disease that is not muscle-invasive have a short follow-up." | 9.12 | Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. ( Gårdmark, T; Jahnson, S; Malmström, PU; Wahlquist, R; Wijkström, H, 2007) |
| "To investigate the combination of raltitrexed and mitomycin-C as first-line chemotherapy treatment in patients with advanced colorectal cancer." | 9.12 | The combination of raltitrexed (Tomudex) and mitomycin-C in the treatment of advanced colorectal cancer--a phase II study. ( Craddock, L; Darby, A; Geldart, T; Iveson, A; Iveson, T; Michels, J; Richardson, L, 2006) |
| "Our findings suggest that the combination of MMC and capecitabine in patients with advanced colorectal cancer pretreated with combination regimens including 5-FU, FA and CPT-11 or 5-FU, FA and L-OHP is safe." | 9.11 | Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. ( Im, YH; Ji, SH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, SH; Lim, DH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS, 2005) |
| "Irinotecan and oxaliplatin are two new agents with promising activity in advanced colorectal cancer." | 9.10 | Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. ( Brugger, S; Depisch, D; Fiebiger, W; Kornek, GV; Kovats, E; Lang, F; Raderer, M; Scheithauer, W; Ullrich-Pur, H; Valencak, J, 2002) |
| "Our results suggest that irinotecan and MMC combination therapy is effective and well tolerated in patients with fluoropyrimidine-resistant metastatic colorectal cancer." | 9.10 | Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. ( Ambo, T; Arai, Y; Denda, T; Hyodo, I; Ohtsu, A; Shirao, K; Yamada, Y, 2003) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 9.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "It appears likely that mitomycin C plus doxorubicin instillation has an equivalent efficacy to BCG as the initial therapy of carcinoma in situ and the combination of them would be the most efficient treatment for the disease." | 9.09 | Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. ( Fukui, I; Igarashi, K; Kojima, SI; Ohya, K; Sekine, H, 2001) |
| "Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs." | 9.09 | A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999) |
| "A randomized multicenter trial was done to compare transurethral resection only to transurethral resection plus adjuvant mitomycin C and bacillus Calmette Guerin (BCG) instillation for treatment of superficial bladder cancer (stage pTa/1 grades 1 to 3 except primary stage pTa grade 1)." | 9.08 | A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. ( Giani, G; Krege, S; Meyer, R; Otto, T; Rübben, H, 1996) |
| "We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy." | 9.08 | Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998) |
| "A search strategy was developed for MEDLINE to identify randomised trials of intravesical gemcitabine for the treatment of non-muscle invasive bladder cancer." | 8.88 | Intravesical gemcitabine for non-muscle invasive bladder cancer. ( Cleves, A; Jones, G; Kynaston, HG; Mason, M; Shelley, M; Wilt, TJ, 2012) |
| "To evaluate the clinical outcome of eyes which underwent primary trabeculectomy with adjunctive mitomycin C (MMC) for primary glaucoma." | 8.79 | Mitomycin C primary trabeculectomy in primary glaucoma of white patients. ( Nuijts, RM; Vernimmen, RC; Webers, CA, 1997) |
| "Background The aim of the study was to evaluate the safety and feasibility of intra-arterial mitomycin C (MMC) infusion after selective internal radiation therapy (SIRT) using Yttrium-90 (90Y) resin microspheres in liver metastatic breast cancer (LMBC) patients." | 7.96 | Sequential intra-arterial infusion of 90Y-resin microspheres and mitomycin C in chemo refractory liver metastatic breast cancer patients: a single centre pilot study. ( Aarts, BM; Beets-Tan, RGH; Deroose, CMALO; Dresen, RC; Klompenhouwer, EG; Maleux, G; Neven, P; Punie, K; Wildiers, H, 2020) |
| "Between 2009 and 2011, 20 patients with intermediate and high risk nonmuscle invasive bladder cancer were treated with intravesical mitomycin C (40 mg) combined with regional hyperthermia." | 7.81 | Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study. ( Crezee, J; de la Rosette, JJ; de Reijke, TM; Geijsen, ED; Koning, CC; Rasch, CR; van Os, RM; Zum Vörde Sive Vörding, PJ, 2015) |
| "To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer." | 7.79 | Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW, 2013) |
| "The aim of this analysis is to evaluate the effect of 5-fluorouracil (5-FU) rechallenge on subsequent response and survival in patients with advanced colorectal cancer (CRC)." | 7.72 | Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. ( Chau, I; Cunningham, D; Hill, M; Norman, AR; Ross, PJ; Yeoh, C, 2003) |
| "Recurrences in non-muscle-invasive bladder cancer are common, despite adjuvant therapies." | 6.82 | Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. ( Arends, TJ; Canepa, G; de Cobelli, O; Maffezzini, M; Moskovitz, B; Nativ, O; van der Heijden, AG; Verweij, F; Witjes, JA, 2016) |
| "Patients with locally advanced anal cancer, T2 (≥4 cm)-4N0-3M0, received weekly standard doses of cetuximab starting 1 week before CRT." | 6.80 | Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. ( Gunnlaugsson, A; Guren, MG; Johnsson, A; Leon, O; Radu, C, 2015) |
| "The long-term bladder cancer-specific mortality was unexpectedly low despite the relatively ineffective instillation therapy and the poor outcome of the patients after progression." | 6.77 | Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17- ( Group, TF; Järvinen, R; Kaasinen, E; Rintala, E, 2012) |
| "Erythropoietin may be lowered by cancer itself or because of chemoradiotherapy." | 6.76 | Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable: implications for radiochemotherapy. ( Cartei, F; Cartei, G; Colombrino, E; Fiorica, F; Giraldi, T; Micucci, M; Plebani, M; Sanzari, MC; Zustovich, F, 2011) |
| "Group B patients were treated with pterygium excision followed by mitomycin C 0." | 6.73 | Treatment of pterygium with conjunctival limbal autograft and mitomycin C--a comparative study. ( Biswas, MC; Chakroborty, M; Islam, MN; Mandal, R; Shaw, C, 2007) |
| "Dipyridamole 75 mg was administered orally three times daily during the FU administration." | 6.73 | Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. ( Barstis, JJ; Bendetti, JK; Isacoff, WH; Jazieh, AR; Macdonald, JS; Philip, PA, 2007) |
| "Thirty-four patients with gastric cancer, 16 after failure of first-line chemotherapy and 18 after failure of at least two prior chemotherapies, were included." | 6.73 | Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study. ( Al-Batran, SE; Bokemeyer, C; Hartmann, JT; Horger, M; Jäger, E; Kanz, L; Königsrainer, A; Meisinger, I; Nehls, O; Pintoffl, JP; Quietzsch, D, 2007) |
| "The response rate and time to disease progression were the primary endpoints, with overall survival as the secondary endpoint." | 6.71 | Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study. ( Amicucci, G; Deraco, M; Di Filippo, F; Fiorentini, G; Guadagni, S; Miotto, D; Patuzzo, R; Pilati, PL; Rossi, CR; Santinami, M; Valenti, M, 2003) |
| "Bladder cancer is the second most common urological malignant disease." | 6.58 | [Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer]. ( Blaschke, S; Christoph, F; König, F; Lebentrau, S; Liehr, UB; Schostak, M, 2018) |
| "In patients with superficial bladder cancer, the occurrence of primary carcinoma in situ was significantly greater in patients with the AA genotype compared with those with the GA or GG genotypes (P = 0." | 5.32 | Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. ( Habuchi, T; Higashi, S; Ito, M; Kamoto, T; Nishiyama, H; Ogawa, O; Tsuchiya, N; Wang, L; Watanabe, J, 2004) |
| "Celecoxib was not shown to reduce the risk of recurrence in intermediate- or high-risk non-muscle-invasive bladder cancer (NMIBC), although celecoxib was associated with delayed time to recurrence in pT1 NMIBC patients." | 5.30 | BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). ( Andrews, S; Blazeby, J; Bogle, R; Brough, R; Burnett, S; Cresswell, J; Cruickshank, C; Hall, E; Huddart, R; Johnson, M; Kelly, JD; Madaan, S; Maynard, L; Mostafid, H; Palmer, A; Porta, N; Protheroe, A; Tan, WS, 2019) |
| "We demonstrated in non-muscle-invasive bladder cancer patients with exceptionally frequent recurrences that the risk of long-term recurrence was reduced from 78-80% to 43-45% if one perioperative plus four weekly mitomycin C instillations were followed by monthly bacillus Calmette-Guérin (BCG) instillations for 1 yr instead of alternating instillations of BCG and interferon-α2b." | 5.20 | Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon ( Aaltomaa, S; Boström, PJ; Järvinen, R; Kaasinen, E; Kallio, J; Liukkonen, T; Marttila, T; Puolakka, VM; Rintala, E; Seppänen, M; Tuhkanen, K; Vaarala, M; Viitanen, J, 2015) |
| "It remains unclear whether people with non-muscle invasive bladder cancer (NMIBC) benefit from intravesical gemcitabine compared to other agents in the primary or recurrent setting following transurethral resection of a bladder tumor." | 5.12 | Intravesical gemcitabine for non-muscle invasive bladder cancer. ( Cleves, A; Dahm, P; Han, MA; Hwang, EC; Hwang, JE; Jung, JH; Maisch, P; Narayan, V, 2021) |
| "To report the 10-year follow-up of a study randomizing between instillations of bacillus Calmette-Guérin (BCG) and mitomycin-C (MMC) for treating high-risk and not muscle-invasive urinary bladder cancer to assess progression, the need for more aggressive treatment and survival (cancer-specific and overall), as many of the published studies comparing different treatments for disease that is not muscle-invasive have a short follow-up." | 5.12 | Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. ( Gårdmark, T; Jahnson, S; Malmström, PU; Wahlquist, R; Wijkström, H, 2007) |
| "To investigate the combination of raltitrexed and mitomycin-C as first-line chemotherapy treatment in patients with advanced colorectal cancer." | 5.12 | The combination of raltitrexed (Tomudex) and mitomycin-C in the treatment of advanced colorectal cancer--a phase II study. ( Craddock, L; Darby, A; Geldart, T; Iveson, A; Iveson, T; Michels, J; Richardson, L, 2006) |
| "Our findings suggest that the combination of MMC and capecitabine in patients with advanced colorectal cancer pretreated with combination regimens including 5-FU, FA and CPT-11 or 5-FU, FA and L-OHP is safe." | 5.11 | Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. ( Im, YH; Ji, SH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, SH; Lim, DH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS, 2005) |
| "Our results suggest that irinotecan and MMC combination therapy is effective and well tolerated in patients with fluoropyrimidine-resistant metastatic colorectal cancer." | 5.10 | Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. ( Ambo, T; Arai, Y; Denda, T; Hyodo, I; Ohtsu, A; Shirao, K; Yamada, Y, 2003) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 5.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "Irinotecan and oxaliplatin are two new agents with promising activity in advanced colorectal cancer." | 5.10 | Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. ( Brugger, S; Depisch, D; Fiebiger, W; Kornek, GV; Kovats, E; Lang, F; Raderer, M; Scheithauer, W; Ullrich-Pur, H; Valencak, J, 2002) |
| "It appears likely that mitomycin C plus doxorubicin instillation has an equivalent efficacy to BCG as the initial therapy of carcinoma in situ and the combination of them would be the most efficient treatment for the disease." | 5.09 | Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. ( Fukui, I; Igarashi, K; Kojima, SI; Ohya, K; Sekine, H, 2001) |
| "We have reported a 33% partial response rate with acceptable toxicity using weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with far advanced biliary tract cancers (BTC)." | 5.09 | Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. ( Chen, JS; Jan, YY; Liau, CT; Lin, YC, 2001) |
| "Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs." | 5.09 | A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999) |
| "We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy." | 5.08 | Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998) |
| "A randomized multicenter trial was done to compare transurethral resection only to transurethral resection plus adjuvant mitomycin C and bacillus Calmette Guerin (BCG) instillation for treatment of superficial bladder cancer (stage pTa/1 grades 1 to 3 except primary stage pTa grade 1)." | 5.08 | A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. ( Giani, G; Krege, S; Meyer, R; Otto, T; Rübben, H, 1996) |
| "A search strategy was developed for MEDLINE to identify randomised trials of intravesical gemcitabine for the treatment of non-muscle invasive bladder cancer." | 4.88 | Intravesical gemcitabine for non-muscle invasive bladder cancer. ( Cleves, A; Jones, G; Kynaston, HG; Mason, M; Shelley, M; Wilt, TJ, 2012) |
| "To evaluate the clinical outcome of eyes which underwent primary trabeculectomy with adjunctive mitomycin C (MMC) for primary glaucoma." | 4.79 | Mitomycin C primary trabeculectomy in primary glaucoma of white patients. ( Nuijts, RM; Vernimmen, RC; Webers, CA, 1997) |
| "Background The aim of the study was to evaluate the safety and feasibility of intra-arterial mitomycin C (MMC) infusion after selective internal radiation therapy (SIRT) using Yttrium-90 (90Y) resin microspheres in liver metastatic breast cancer (LMBC) patients." | 3.96 | Sequential intra-arterial infusion of 90Y-resin microspheres and mitomycin C in chemo refractory liver metastatic breast cancer patients: a single centre pilot study. ( Aarts, BM; Beets-Tan, RGH; Deroose, CMALO; Dresen, RC; Klompenhouwer, EG; Maleux, G; Neven, P; Punie, K; Wildiers, H, 2020) |
| "Hyperthermic mitomycin (HM) is a novel treatment modality for selected patients with high-risk non-muscle invasive bladder cancer (NMIBC)." | 3.83 | Predictive Factors for Time to Progression after Hyperthermic Mitomycin C Treatment for High-Risk Non-Muscle Invasive Urothelial Carcinoma of the Bladder: An Observational Cohort Study of 97 Patients. ( Ayres, BE; Bailey, M; Chiocchia, V; Dutton, S; Issa, R; Le Roux, P; Pai, A; Perry, MJ; Sooriakumaran, P; Swinn, M, 2016) |
| "Between 2009 and 2011, 20 patients with intermediate and high risk nonmuscle invasive bladder cancer were treated with intravesical mitomycin C (40 mg) combined with regional hyperthermia." | 3.81 | Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study. ( Crezee, J; de la Rosette, JJ; de Reijke, TM; Geijsen, ED; Koning, CC; Rasch, CR; van Os, RM; Zum Vörde Sive Vörding, PJ, 2015) |
| "To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer." | 3.79 | Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW, 2013) |
| "The aim of this analysis is to evaluate the effect of 5-fluorouracil (5-FU) rechallenge on subsequent response and survival in patients with advanced colorectal cancer (CRC)." | 3.72 | Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. ( Chau, I; Cunningham, D; Hill, M; Norman, AR; Ross, PJ; Yeoh, C, 2003) |
| "Recurrences in non-muscle-invasive bladder cancer are common, despite adjuvant therapies." | 2.82 | Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. ( Arends, TJ; Canepa, G; de Cobelli, O; Maffezzini, M; Moskovitz, B; Nativ, O; van der Heijden, AG; Verweij, F; Witjes, JA, 2016) |
| "Patients with locally advanced anal cancer, T2 (≥4 cm)-4N0-3M0, received weekly standard doses of cetuximab starting 1 week before CRT." | 2.80 | Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. ( Gunnlaugsson, A; Guren, MG; Johnsson, A; Leon, O; Radu, C, 2015) |
| "The long-term bladder cancer-specific mortality was unexpectedly low despite the relatively ineffective instillation therapy and the poor outcome of the patients after progression." | 2.77 | Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17- ( Group, TF; Järvinen, R; Kaasinen, E; Rintala, E, 2012) |
| "Mitomycin C treatment, selected on the basis of its robust preclinical activity in a personalized xenograft generated from the patient's tumor, resulted in long-lasting (36+ months) tumor response." | 2.76 | Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. ( De Jesus-Acosta, A; Donehower, R; Eshleman, JR; Garrido-Laguna, I; Hidalgo, M; Hruban, RH; Jones, S; Klein, A; Laheru, D; Maitra, A; Rajeshkumar, NV; Villarroel, MC, 2011) |
| "Erythropoietin may be lowered by cancer itself or because of chemoradiotherapy." | 2.76 | Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable: implications for radiochemotherapy. ( Cartei, F; Cartei, G; Colombrino, E; Fiorica, F; Giraldi, T; Micucci, M; Plebani, M; Sanzari, MC; Zustovich, F, 2011) |
| "Although fatigue was the most frequently encountered toxicity safety profiles were generally predictable and manageable." | 2.73 | Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study. ( Cho, EK; Chung, M; Hong, J; Kim, YS; Lee, JH; Lee, WK; Nam, E; Park, J; Park, SH; Shin, DB, 2008) |
| "Dipyridamole 75 mg was administered orally three times daily during the FU administration." | 2.73 | Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. ( Barstis, JJ; Bendetti, JK; Isacoff, WH; Jazieh, AR; Macdonald, JS; Philip, PA, 2007) |
| "Group B patients were treated with pterygium excision followed by mitomycin C 0." | 2.73 | Treatment of pterygium with conjunctival limbal autograft and mitomycin C--a comparative study. ( Biswas, MC; Chakroborty, M; Islam, MN; Mandal, R; Shaw, C, 2007) |
| "Thirty-four patients with gastric cancer, 16 after failure of first-line chemotherapy and 18 after failure of at least two prior chemotherapies, were included." | 2.73 | Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study. ( Al-Batran, SE; Bokemeyer, C; Hartmann, JT; Horger, M; Jäger, E; Kanz, L; Königsrainer, A; Meisinger, I; Nehls, O; Pintoffl, JP; Quietzsch, D, 2007) |
| "Of 148 newly diagnosed patients with T1 bladder cancer 142 were prospectively randomized in 2 groups between January 2001 and January 2005." | 2.72 | The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. ( Divrik, RT; Ozen, H; Yildirim, U; Zorlu, F, 2006) |
| "The response rate and time to disease progression were the primary endpoints, with overall survival as the secondary endpoint." | 2.71 | Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study. ( Amicucci, G; Deraco, M; Di Filippo, F; Fiorentini, G; Guadagni, S; Miotto, D; Patuzzo, R; Pilati, PL; Rossi, CR; Santinami, M; Valenti, M, 2003) |
| "Patients with G3 bladder tumors (Stage Ta or T1) were treated with combined intravesical chemotherapy with mitomycin-C and local radiofrequency hyperthermia of the bladder wall." | 2.71 | Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. ( Colombo, R; Gofrit, ON; Leib, Z; Naspro, R; Nativ, O; Pode, D; Shapiro, A; Sidi, A; van der Heijden, AG; Witjes, JA, 2004) |
| "Secondary objectives were time to disease progression, response rates, evaluation of toxicity, disease-related symptoms, World Health Organization performance status (PS), and quality of life (QoL)." | 2.71 | Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. ( Anderson, H; Ashcroft, L; Beresford, C; Burt, PA; Clemons, M; Danson, S; Dowd, I; Fairve-Finn, C; Hassan, J; Middleton, MR; O'Byrne, KJ; Ranson, M; Stout, R; Thatcher, N, 2003) |
| "A retrospective study of 46 patients treated for peritoneal carcinomatosis from colon adenocarcinoma was performed." | 2.71 | Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. ( Campana, L; Foletto, M; Lise, M; Mocellin, S; Nitti, D; Pilati, P; Rossi, CR, 2003) |
| "Mitomycin C was administered every 6 weeks and treatment was continued as long as tolerance and patient compliance allowed, and no progression was observed." | 2.69 | Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial. ( de Reijke, TM; Keuppens, FI; Kliment, J; Rea, LA; Robinson, MR; Sylvester, RJ; Whelan, P, 1999) |
| "Bladder cancer is the second most common urological malignant disease." | 2.58 | [Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer]. ( Blaschke, S; Christoph, F; König, F; Lebentrau, S; Liehr, UB; Schostak, M, 2018) |
| "There was no disease progression in either treatment arm at three months' follow-up." | 2.55 | Intravesical electromotive drug administration for non-muscle invasive bladder cancer. ( Dahm, P; Gudeloglu, A; Jung, JH; Kiziloz, H; Konety, BR; Kuntz, GM; Miller, A, 2017) |
| "Non-muscle-invasive bladder cancers form a heterogeneous group of tumours with varying recurrence and progression rates." | 2.45 | Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer. ( Horvath, A; Mostafid, H, 2009) |
| "Chest X-rays and CT scans revealed atelectasis of the right middle lobe." | 2.41 | A solitary bronchial papilloma with malignant changes. ( Inoue, Y; Ishii, H; Ito, M; Ito, T; Kimino, K; Kishikawa, M; Kohno, S; Nakashima, M; Oka, M, 2001) |
| "Hyperthermic Mitomycin using the HIVEC® device is a rather safe and well tolerated treatment." | 1.56 | [Safety of Hyperthermic IntraVEsical Chemotherapy (HIVEC) for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients]. ( Branger, N; Dermeche, S; Fakhfakh, S; Gravis, G; Marquette, T; Maubon, T; Pignot, G; Rybikowski, S; Verde, KL; Walz, J, 2020) |
| "In gene expression analysis of bladder cancer patients, the survival of patients with high RAD54L expression was shorter with cancer progression than in patients with low RAD54L expression." | 1.56 | E2F1 Promotes Progression of Bladder Cancer by Modulating RAD54L Involved in Homologous Recombination Repair. ( Baek, SW; Choi, YH; Chu, IS; Chung, JW; Jeong, MS; Kim, SK; Kim, WT; Lee, JH; Leem, SH; Mun, JY; Park, WY; Roh, YG; Yang, GE, 2020) |
| "Thirty‑six C57BL/6J mice bearing bladder cancer were randomly divided into six treatment groups as follows: control, BCG, MMC, ADM, MMC‑BCG and ADM‑BCG." | 1.51 | Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment. ( Fujimoto, K; Gotoh, D; Hori, S; Iida, K; Itami, Y; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, K; Onishi, S; Tanaka, N; Tatsumi, Y, 2019) |
| "Patients with brain metastases of triple negative breast cancer (TNBC) have a poor prognosis owing to the lack of targeted therapies, the aggressive nature of TNBC, and the presence of the blood-brain barrier (BBB) that blocks penetration of most drugs." | 1.51 | Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages. ( Cai, P; He, C; Henderson, JT; Lip, H; Rauth, AM; Wang, Z; Wu, XY; Zhang, T, 2019) |
| "Patients with unresectable recurrent rectal cancer that progresses after systemic chemotherapy and radiotherapy are candidates for palliation with hypoxic pelvic perfusion (HPP)." | 1.48 | Palliation with a multimodality treatment including hypoxic pelvic perfusion for unresectable recurrent rectal cancer: outcomes based on a retrospective study. ( Bencivenga, M; Clementi, M; Fiorentini, C; Guadagni, S; Kusamura, S; Masedu, F, 2018) |
| "For patients with liver metastases from gastric cancer (LMGC), combination chemotherapy with fluoropyrimidines and platinum agents has been recognized as standard treatment." | 1.43 | Hepatic arterial infusion chemotherapy using fluorouracil, epirubicin, and mitomycin C for patients with liver metastases from gastric cancer after treatment failure of systemic S-1 plus cisplatin. ( Ohi, H; Ozaki, T; Seki, H; Yabusaki, H, 2016) |
| "Mean time to disease progression was 2." | 1.39 | Nonselective transarterial chemoperfusion: a palliative treatment for malignant pleural mesothelioma. ( Gurung, J; Lindemayr, S; Mbalisike, EC; Naguib, NN; Nour-Eldin, NE; Vogl, TJ; Zangos, S, 2013) |
| "Median time to disease progression was 4 months, and median survival was 9+ months." | 1.39 | Is there still a role for mitomycin-based combination chemotherapy in treating patients with nonsmall cell lung cancer? A single institution experience. ( Antonelli, G; Blandino, R; Calì, S; Ferraù, F; Malaponte, E; Panebianco, V; Vitale, FV, 2013) |
| "Patients had liver metastasis from colorectal carcinomas, breast cancer, lung cancer and carcinoid tumors." | 1.38 | Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol. ( Akhlaghpoor, S; Amoui, M; Aziz-Ahari, A; Poorbeigi, H; Sheybani, S; Tolooee, S, 2012) |
| "We conclude that minimal residual disease, compared with macroscopically complete cytoreduction, correlated to failure in critical anatomical areas, suggesting the need for maximal cytoreductive surgical efforts." | 1.35 | Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). ( Baratti, D; Cabras, AD; Deraco, M; Dileo, P; Kusamura, S; Laterza, B, 2009) |
| "Finally, the growth and metastasis of KGN cells injected subcutaneously (s." | 1.35 | Spontaneous transformation of human granulosa cell tumours into an aggressive phenotype: a metastasis model cell line. ( Imai, M; Muraki, M; Saito, H; Seiki, M; Takahashi, Y; Takamatsu, K, 2008) |
| "Posterior glottic stenosis (PGS) is a disabling disease commonly induced by endolaryngeal injury from intubation or surgery." | 1.33 | Prevention of posterior glottic stenosis by mitomycin C. ( Roh, JL, 2005) |
| "Therefore, genomic instability generated NCCAs are a key driving force in cancer progression." | 1.33 | Stochastic cancer progression driven by non-clonal chromosome aberrations. ( Bremer, SW; Heng, HH; Liu, G; Reddy, PV; Stevens, JB; Tainsky, MA; Wang, YA; Wu, GS; Ye, CJ; Ye, KJ, 2006) |
| "In patients with superficial bladder cancer, the occurrence of primary carcinoma in situ was significantly greater in patients with the AA genotype compared with those with the GA or GG genotypes (P = 0." | 1.32 | Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. ( Habuchi, T; Higashi, S; Ito, M; Kamoto, T; Nishiyama, H; Ogawa, O; Tsuchiya, N; Wang, L; Watanabe, J, 2004) |
| "We study the efficacy of treating ocular cicatricial pemphigoid (OCP) with subconjuctival mitomycin C (MMC)." | 1.31 | [Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid]. ( Celis Sánchez, J; García Largacha, M; González del Valle, F; López Ferrando, N; Ortiz de la Torre, MJ, 2002) |
| "In patients with pancreatic cancer, the overall response rate was 42% with a median survival of 8 months." | 1.31 | Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen. ( Gallagher, CJ; Shamash, J; Slater, S; Slevin, ML; Wilson, P, 2002) |
| "The outcome of patients with mucinous appendiceal neoplasms with peritoneal surface dissemination has changed as a result of a better understanding of the clinical and pathologic features of this disease." | 1.31 | Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients. ( Esquivel, J; Sugarbaker, PH, 2001) |
| "About one-third of patients with gastric cancer are unresectable at the time of diagnosis." | 1.30 | Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. ( Cho, JY; Chung, HC; Kim, BS; Kim, CB; Kim, JH; Min, JS; Noh, SH; Park, JO; Rha, SY; Roh, JK; You, NC, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 21 (14.38) | 18.2507 |
| 2000's | 68 (46.58) | 29.6817 |
| 2010's | 51 (34.93) | 24.3611 |
| 2020's | 6 (4.11) | 2.80 |
| Authors | Studies |
|---|---|
| Ghelardi, F | 1 |
| Raimondi, A | 1 |
| Morano, F | 1 |
| Randon, G | 1 |
| Pannone, A | 1 |
| Guaglio, M | 1 |
| Mazzoli, G | 1 |
| Nasca, V | 1 |
| Milione, M | 1 |
| Leoncini, G | 1 |
| Sabella, G | 1 |
| Greco, GF | 1 |
| Lampis, BR | 1 |
| Galassi, M | 1 |
| Delfanti, S | 1 |
| Nannini, M | 1 |
| Intini, R | 1 |
| Baratti, D | 2 |
| Di Bartolomeo, M | 1 |
| Deraco, M | 4 |
| Pietrantonio, F | 1 |
| Marquette, T | 1 |
| Walz, J | 1 |
| Rybikowski, S | 1 |
| Maubon, T | 1 |
| Branger, N | 1 |
| Fakhfakh, S | 1 |
| Verde, KL | 1 |
| Dermeche, S | 1 |
| Gravis, G | 1 |
| Pignot, G | 1 |
| Hentzen, JEKR | 1 |
| van der Plas, WY | 1 |
| Kuipers, H | 1 |
| Ramcharan, S | 1 |
| Been, LB | 1 |
| Hoogwater, FJH | 1 |
| van Ginkel, RJ | 1 |
| van Dam, GM | 1 |
| Hemmer, PHJ | 1 |
| Kruijff, S | 1 |
| Aarts, BM | 1 |
| Klompenhouwer, EG | 1 |
| Dresen, RC | 1 |
| Deroose, CMALO | 1 |
| Beets-Tan, RGH | 1 |
| Punie, K | 1 |
| Neven, P | 1 |
| Wildiers, H | 1 |
| Maleux, G | 1 |
| Mun, JY | 1 |
| Baek, SW | 1 |
| Park, WY | 1 |
| Kim, WT | 1 |
| Kim, SK | 1 |
| Roh, YG | 1 |
| Jeong, MS | 1 |
| Yang, GE | 1 |
| Lee, JH | 3 |
| Chung, JW | 1 |
| Choi, YH | 1 |
| Chu, IS | 1 |
| Leem, SH | 1 |
| Han, MA | 1 |
| Maisch, P | 1 |
| Jung, JH | 2 |
| Hwang, JE | 1 |
| Narayan, V | 1 |
| Cleves, A | 2 |
| Hwang, EC | 1 |
| Dahm, P | 2 |
| Gözen, AS | 1 |
| Umari, P | 1 |
| Scheitlin, W | 1 |
| Su, FE | 1 |
| Akin, Y | 1 |
| Rassweiler, J | 1 |
| Naito, T | 1 |
| Fujiwara, M | 1 |
| Miki, T | 1 |
| Araki, R | 1 |
| Fujiwara, A | 1 |
| Shiode, Y | 1 |
| Morizane, Y | 1 |
| Nagayama, M | 1 |
| Shiraga, F | 1 |
| Gudeloglu, A | 1 |
| Kiziloz, H | 1 |
| Kuntz, GM | 1 |
| Miller, A | 1 |
| Konety, BR | 1 |
| Christoph, F | 1 |
| König, F | 1 |
| Lebentrau, S | 1 |
| Blaschke, S | 1 |
| Liehr, UB | 1 |
| Schostak, M | 1 |
| Crijnen, J | 1 |
| De Reijke, TM | 3 |
| Guadagni, S | 3 |
| Clementi, M | 1 |
| Bencivenga, M | 1 |
| Kusamura, S | 2 |
| Fiorentini, C | 1 |
| Masedu, F | 1 |
| Kelly, JD | 1 |
| Tan, WS | 1 |
| Porta, N | 1 |
| Mostafid, H | 2 |
| Huddart, R | 1 |
| Protheroe, A | 1 |
| Bogle, R | 1 |
| Blazeby, J | 1 |
| Palmer, A | 1 |
| Cresswell, J | 1 |
| Johnson, M | 1 |
| Brough, R | 1 |
| Madaan, S | 1 |
| Andrews, S | 1 |
| Cruickshank, C | 1 |
| Burnett, S | 1 |
| Maynard, L | 1 |
| Hall, E | 1 |
| Lenis, AT | 1 |
| Asanad, K | 1 |
| Blaibel, M | 1 |
| Donin, NM | 1 |
| Chamie, K | 1 |
| Hori, S | 1 |
| Miyake, M | 1 |
| Tatsumi, Y | 1 |
| Morizawa, Y | 1 |
| Nakai, Y | 1 |
| Onishi, S | 1 |
| Onishi, K | 1 |
| Iida, K | 1 |
| Gotoh, D | 1 |
| Itami, Y | 1 |
| Tanaka, N | 1 |
| Fujimoto, K | 1 |
| Zhang, T | 1 |
| Lip, H | 1 |
| He, C | 1 |
| Cai, P | 1 |
| Wang, Z | 1 |
| Henderson, JT | 1 |
| Rauth, AM | 1 |
| Wu, XY | 1 |
| Yu, SJ | 1 |
| Jang, ES | 1 |
| Cho, EJ | 1 |
| Kwak, MS | 1 |
| Yoon, JH | 1 |
| Lee, HS | 1 |
| Kim, CY | 1 |
| Kim, YJ | 1 |
| Saif, MW | 1 |
| Kaley, K | 1 |
| Brennan, M | 1 |
| Garcon, MC | 1 |
| Rodriguez, G | 1 |
| Nasyrov, AR | 1 |
| Pirtskhalava, TL | 1 |
| Korovina, IaV | 1 |
| Maffezzini, M | 2 |
| Campodonico, F | 1 |
| Canepa, G | 2 |
| Manuputty, EE | 1 |
| Tamagno, S | 1 |
| Puntoni, M | 1 |
| López, E | 1 |
| Domenech, A | 1 |
| Ferrándiz, MJ | 1 |
| Frias, MJ | 1 |
| Ardanuy, C | 1 |
| Ramirez, M | 1 |
| García, E | 1 |
| Liñares, J | 1 |
| de la Campa, AG | 1 |
| Siegel, EM | 1 |
| Eschrich, S | 1 |
| Winter, K | 1 |
| Riggs, B | 1 |
| Berglund, A | 1 |
| Ajidahun, A | 1 |
| Simko, J | 1 |
| Moughan, J | 1 |
| Ajani, J | 1 |
| Magliocco, A | 1 |
| Elahi, A | 1 |
| Hoffe, S | 1 |
| Shibata, D | 1 |
| Huang, J | 1 |
| Li, Q | 1 |
| Zheng, Y | 1 |
| Shen, J | 1 |
| Li, B | 1 |
| Zou, R | 1 |
| Wang, J | 1 |
| Yuan, Y | 1 |
| Seisen, T | 1 |
| Colin, P | 1 |
| Rouprêt, M | 2 |
| Järvinen, R | 2 |
| Marttila, T | 1 |
| Kaasinen, E | 3 |
| Rintala, E | 2 |
| Aaltomaa, S | 1 |
| Kallio, J | 1 |
| Liukkonen, T | 1 |
| Puolakka, VM | 1 |
| Seppänen, M | 1 |
| Tuhkanen, K | 1 |
| Vaarala, M | 1 |
| Viitanen, J | 1 |
| Boström, PJ | 1 |
| Yoshioka, M | 1 |
| Shibata, S | 1 |
| Uchinami, H | 1 |
| Watanabe, G | 1 |
| Miyazawa, H | 1 |
| Iida, M | 1 |
| Yoshida, M | 1 |
| Yoshioka, T | 1 |
| Nanjo, H | 1 |
| Yamamoto, Y | 1 |
| Sylvester, RJ | 2 |
| Oosterlinck, W | 1 |
| Holmang, S | 1 |
| Sydes, MR | 1 |
| Birtle, A | 1 |
| Gudjonsson, S | 1 |
| De Nunzio, C | 1 |
| Okamura, K | 1 |
| Solsona, E | 2 |
| Ali-El-Dein, B | 1 |
| Tatar, CA | 1 |
| Inman, BA | 1 |
| N'Dow, J | 1 |
| Oddens, JR | 1 |
| Babjuk, M | 1 |
| Geijsen, ED | 1 |
| Koning, CC | 1 |
| Zum Vörde Sive Vörding, PJ | 1 |
| de la Rosette, JJ | 1 |
| Rasch, CR | 1 |
| van Os, RM | 1 |
| Crezee, J | 1 |
| Sooriakumaran, P | 1 |
| Chiocchia, V | 1 |
| Dutton, S | 1 |
| Pai, A | 1 |
| Ayres, BE | 1 |
| Le Roux, P | 1 |
| Swinn, M | 1 |
| Bailey, M | 1 |
| Perry, MJ | 1 |
| Issa, R | 1 |
| Seki, H | 1 |
| Ohi, H | 1 |
| Ozaki, T | 1 |
| Yabusaki, H | 1 |
| Leon, O | 1 |
| Guren, MG | 1 |
| Radu, C | 1 |
| Gunnlaugsson, A | 1 |
| Johnsson, A | 1 |
| Motamedinia, P | 1 |
| Keheila, M | 1 |
| Leavitt, DA | 1 |
| Rastinehad, AR | 1 |
| Okeke, Z | 1 |
| Smith, AD | 1 |
| Arends, TJ | 1 |
| Nativ, O | 2 |
| de Cobelli, O | 1 |
| Verweij, F | 1 |
| Moskovitz, B | 1 |
| van der Heijden, AG | 2 |
| Witjes, JA | 3 |
| Mouli, SK | 1 |
| Hickey, R | 1 |
| Thornburg, B | 1 |
| Sato, KT | 1 |
| Desai, K | 1 |
| Gabr, A | 1 |
| Kallini, JR | 1 |
| Niemeri, H | 1 |
| Kircher, S | 1 |
| Mulcahy, MF | 1 |
| Benson Iii, AB | 1 |
| Gupta, R | 1 |
| Salem, R | 1 |
| Lewandowski, RJ | 1 |
| Mbeutcha, A | 1 |
| Shariat, SF | 2 |
| Rieken, M | 1 |
| Rink, M | 1 |
| Xylinas, E | 1 |
| Seitz, C | 1 |
| Lucca, I | 1 |
| Mathieu, R | 1 |
| Briganti, A | 1 |
| Karakiewicz, PI | 1 |
| Klatte, T | 1 |
| Zhuo, C | 1 |
| Li, X | 1 |
| Zhuang, H | 1 |
| Tian, S | 1 |
| Cui, H | 1 |
| Jiang, R | 1 |
| Liu, C | 1 |
| Tao, R | 1 |
| Lin, X | 1 |
| Park, SH | 1 |
| Kim, YS | 1 |
| Hong, J | 1 |
| Park, J | 1 |
| Nam, E | 1 |
| Cho, EK | 1 |
| Shin, DB | 1 |
| Lee, WK | 1 |
| Chung, M | 1 |
| Saint, F | 1 |
| Imai, M | 1 |
| Muraki, M | 1 |
| Takamatsu, K | 1 |
| Saito, H | 1 |
| Seiki, M | 1 |
| Takahashi, Y | 1 |
| Horvath, A | 1 |
| Cabras, AD | 1 |
| Dileo, P | 1 |
| Laterza, B | 1 |
| Vogl, TJ | 3 |
| Gruber, T | 1 |
| Balzer, JO | 1 |
| Eichler, K | 1 |
| Hammerstingl, R | 1 |
| Zangos, S | 3 |
| Fraunholz, I | 1 |
| Weiss, C | 1 |
| Eberlein, K | 1 |
| Haberl, A | 1 |
| Rödel, C | 2 |
| Li, J | 1 |
| Dai, CH | 1 |
| Yu, LC | 1 |
| Chen, P | 1 |
| Li, XQ | 1 |
| Shi, SB | 1 |
| Wu, JR | 1 |
| Folgar, FA | 1 |
| de Moraes, CG | 1 |
| Prata, TS | 1 |
| Teng, CC | 1 |
| Tello, C | 1 |
| Ritch, R | 1 |
| Liebmann, JM | 1 |
| Aoyama, A | 1 |
| Ishida, K | 1 |
| Sawada, A | 1 |
| Yamamoto, T | 2 |
| Wolff, HA | 1 |
| Bosch, J | 1 |
| Jung, K | 1 |
| Overbeck, T | 1 |
| Hennies, S | 1 |
| Matthias, C | 1 |
| Hess, CF | 1 |
| Roedel, RM | 1 |
| Christiansen, H | 1 |
| Chua, TC | 1 |
| Al-Zahrani, A | 1 |
| Saxena, A | 1 |
| Liauw, W | 1 |
| Zhao, J | 1 |
| Morris, DL | 1 |
| Cascinu, S | 1 |
| Galizia, E | 1 |
| Labianca, R | 1 |
| Ferraù, F | 2 |
| Pucci, F | 1 |
| Silva, RR | 1 |
| Luppi, G | 1 |
| Beretta, GD | 1 |
| Berardi, R | 1 |
| Scartozzi, M | 1 |
| Al-Batran, SE | 2 |
| Güntner, M | 1 |
| Pauligk, C | 1 |
| Scholz, M | 1 |
| Chen, R | 1 |
| Beiss, B | 1 |
| Stopatschinskaja, S | 1 |
| Lerbs, W | 1 |
| Harbeck, N | 1 |
| Jäger, E | 2 |
| Villarroel, MC | 1 |
| Rajeshkumar, NV | 1 |
| Garrido-Laguna, I | 1 |
| De Jesus-Acosta, A | 1 |
| Jones, S | 1 |
| Maitra, A | 1 |
| Hruban, RH | 1 |
| Eshleman, JR | 1 |
| Klein, A | 1 |
| Laheru, D | 1 |
| Donehower, R | 1 |
| Hidalgo, M | 1 |
| Mansoor, M | 1 |
| Ali, S | 1 |
| Fasihuddin, Q | 1 |
| Baloch, MU | 1 |
| Cereda, S | 1 |
| Reni, M | 1 |
| Rognone, A | 1 |
| Fugazza, C | 1 |
| Ghidini, M | 1 |
| Ceraulo, D | 1 |
| Brioschi, M | 1 |
| Nicoletti, R | 1 |
| Villa, E | 1 |
| Zhang, HH | 1 |
| Qi, F | 1 |
| Shi, YR | 1 |
| Miao, JG | 1 |
| Zhou, M | 1 |
| He, W | 1 |
| Chen, MF | 1 |
| Li, Y | 1 |
| Zu, XB | 1 |
| Qi, L | 1 |
| Zarnowski, T | 1 |
| Kosior-Jarecka, E | 1 |
| Cartei, G | 1 |
| Colombrino, E | 1 |
| Sanzari, MC | 1 |
| Plebani, M | 1 |
| Micucci, M | 1 |
| Fiorica, F | 1 |
| Giraldi, T | 1 |
| Zustovich, F | 1 |
| Cartei, F | 1 |
| Jones, G | 1 |
| Wilt, TJ | 1 |
| Mason, M | 1 |
| Kynaston, HG | 1 |
| Shelley, M | 1 |
| Morse, MA | 1 |
| Hanks, BA | 1 |
| Suhocki, P | 1 |
| Doan, PL | 1 |
| Liu, EA | 1 |
| Frost, P | 1 |
| Bernard, SA | 1 |
| Tsai, A | 1 |
| Moore, DT | 1 |
| O'Neil, BH | 1 |
| Cutress, ML | 1 |
| Stewart, GD | 1 |
| Zakikhani, P | 1 |
| Phipps, S | 1 |
| Thomas, BG | 1 |
| Tolley, DA | 1 |
| Group, TF | 1 |
| Irvine, F | 1 |
| Kumarasamy, M | 1 |
| Kemp, E | 1 |
| Roberts, F | 1 |
| Vitale, FV | 1 |
| Malaponte, E | 1 |
| Calì, S | 1 |
| Antonelli, G | 1 |
| Panebianco, V | 1 |
| Blandino, R | 1 |
| Akhlaghpoor, S | 1 |
| Aziz-Ahari, A | 1 |
| Amoui, M | 1 |
| Tolooee, S | 1 |
| Poorbeigi, H | 1 |
| Sheybani, S | 1 |
| Lindemayr, S | 2 |
| Naguib, NN | 1 |
| Gurung, J | 1 |
| Nour-Eldin, NE | 1 |
| Mbalisike, EC | 1 |
| Hofheinz, RD | 2 |
| Hartung, G | 1 |
| Samel, S | 1 |
| Hochhaus, A | 2 |
| Pichlmeier, U | 2 |
| Post, S | 1 |
| Hehlmann, R | 2 |
| Queisser, W | 1 |
| Gebbia, V | 1 |
| Galetta, D | 1 |
| Riccardi, F | 1 |
| Gridelli, C | 1 |
| Durini, E | 1 |
| Borsellino, N | 1 |
| Gebbia, N | 1 |
| Valdesi, M | 1 |
| Caruso, M | 1 |
| Valenza, R | 1 |
| Pezzella, G | 1 |
| Colucci, G | 2 |
| Celis Sánchez, J | 1 |
| López Ferrando, N | 1 |
| García Largacha, M | 1 |
| González del Valle, F | 1 |
| Ortiz de la Torre, MJ | 1 |
| Francini, G | 1 |
| Petrioli, R | 1 |
| Messinese, S | 1 |
| Pozzessere, D | 1 |
| Marsili, S | 1 |
| Correale, P | 1 |
| Sabatino, M | 1 |
| Fiaschi, AI | 1 |
| Slater, S | 1 |
| Shamash, J | 2 |
| Wilson, P | 2 |
| Gallagher, CJ | 1 |
| Slevin, ML | 1 |
| Santinami, M | 1 |
| Patuzzo, R | 1 |
| Pilati, PL | 2 |
| Miotto, D | 1 |
| Rossi, CR | 2 |
| Fiorentini, G | 1 |
| Di Filippo, F | 1 |
| Valenti, M | 1 |
| Amicucci, G | 1 |
| Weisser, A | 1 |
| Willer, A | 1 |
| Steele, JP | 1 |
| Nystrom, M | 1 |
| Ansell, W | 1 |
| Oliver, RT | 1 |
| Yamada, Y | 1 |
| Shirao, K | 1 |
| Hyodo, I | 1 |
| Arai, Y | 1 |
| Denda, T | 1 |
| Ambo, T | 1 |
| Ohtsu, A | 1 |
| Pilati, P | 1 |
| Mocellin, S | 1 |
| Foletto, M | 1 |
| Campana, L | 1 |
| Nitti, D | 1 |
| Lise, M | 1 |
| Danson, S | 1 |
| Middleton, MR | 1 |
| O'Byrne, KJ | 1 |
| Clemons, M | 1 |
| Ranson, M | 1 |
| Hassan, J | 1 |
| Anderson, H | 1 |
| Burt, PA | 1 |
| Fairve-Finn, C | 1 |
| Stout, R | 1 |
| Dowd, I | 1 |
| Ashcroft, L | 1 |
| Beresford, C | 1 |
| Thatcher, N | 1 |
| Di Stasi, SM | 1 |
| Giannantoni, A | 1 |
| Stephen, RL | 1 |
| Capelli, G | 1 |
| Navarra, P | 1 |
| Massoud, R | 1 |
| Vespasiani, G | 1 |
| Yeoh, C | 1 |
| Chau, I | 1 |
| Cunningham, D | 1 |
| Norman, AR | 1 |
| Hill, M | 1 |
| Ross, PJ | 1 |
| Scagliotti, GV | 1 |
| Fossati, R | 1 |
| Torri, V | 1 |
| Crinò, L | 1 |
| Giaccone, G | 1 |
| Silvano, G | 1 |
| Martelli, M | 1 |
| Clerici, M | 1 |
| Cognetti, F | 1 |
| Tonato, M | 1 |
| Peyromaure, M | 1 |
| Zerbib, M | 1 |
| Gofrit, ON | 1 |
| Shapiro, A | 1 |
| Pode, D | 1 |
| Sidi, A | 1 |
| Leib, Z | 1 |
| Naspro, R | 1 |
| Colombo, R | 1 |
| Giroux, MF | 1 |
| Baum, RA | 2 |
| Soulen, MC | 3 |
| Böhle, A | 1 |
| Bock, PR | 1 |
| Pandya, KJ | 1 |
| Lefkopoulou, M | 1 |
| Petrelli, NJ | 1 |
| Vaughn, DJ | 1 |
| Smith, TJ | 1 |
| Harris, JE | 1 |
| Haller, DG | 1 |
| Tuinmann, G | 1 |
| Hegewisch-Becker, S | 1 |
| Zschaber, R | 1 |
| Kehr, A | 1 |
| Schulz, J | 1 |
| Hossfeld, DK | 1 |
| Ito, M | 2 |
| Habuchi, T | 1 |
| Watanabe, J | 1 |
| Higashi, S | 1 |
| Nishiyama, H | 1 |
| Wang, L | 1 |
| Tsuchiya, N | 1 |
| Kamoto, T | 1 |
| Ogawa, O | 1 |
| Loibl, S | 1 |
| von Minckwitz, G | 1 |
| Schwedler, K | 1 |
| Schmidt, KA | 1 |
| Höper, D | 1 |
| Kaufmann, M | 1 |
| Costa, SD | 1 |
| Peer, D | 1 |
| Dekel, Y | 1 |
| Melikhov, D | 1 |
| Margalit, R | 1 |
| Assisi, D | 1 |
| Grassi, A | 1 |
| La Penta, R | 1 |
| Stigliano, V | 1 |
| Greco, C | 1 |
| Cianciulli, AM | 1 |
| Giannarelli, D | 1 |
| Casale, V | 1 |
| Wetter, A | 1 |
| Lim, DH | 1 |
| Park, YS | 1 |
| Park, BB | 1 |
| Ji, SH | 1 |
| Lee, J | 1 |
| Park, KW | 1 |
| Kang, JH | 1 |
| Lee, SH | 1 |
| Park, JO | 2 |
| Kim, K | 1 |
| Kim, WS | 1 |
| Jung, CW | 1 |
| Im, YH | 1 |
| Kang, WK | 1 |
| Park, K | 1 |
| Roh, JL | 1 |
| Iaffaioli, RV | 1 |
| Facchini, G | 1 |
| Tortoriello, A | 1 |
| Crovella, F | 1 |
| Romano, G | 1 |
| Formato, R | 1 |
| Santangelo, M | 1 |
| Barletta, E | 1 |
| Fiore, F | 1 |
| Iaccarino, V | 1 |
| Memoli, B | 1 |
| D'Angelo, R | 1 |
| Rossi, R | 1 |
| Pignata, S | 1 |
| Daniele, B | 1 |
| Rosati, G | 1 |
| Massidda, B | 1 |
| Mantovani, G | 1 |
| Di Salvo, E | 1 |
| Marzano, N | 1 |
| Memeo, V | 1 |
| Parisi, V | 1 |
| Mallarini, G | 1 |
| Harland, SJ | 1 |
| Morise, Z | 1 |
| Sugioka, A | 1 |
| Kato, R | 1 |
| Fujita, J | 1 |
| Hoshimoto, S | 1 |
| Kato, T | 1 |
| Sugarbaker, PH | 2 |
| Alderman, R | 1 |
| Edwards, G | 1 |
| Marquardt, CE | 1 |
| Gushchin, V | 1 |
| Esquivel, J | 2 |
| Chang, D | 1 |
| Divrik, RT | 1 |
| Yildirim, U | 1 |
| Zorlu, F | 1 |
| Ozen, H | 1 |
| Heng, HH | 1 |
| Stevens, JB | 1 |
| Liu, G | 1 |
| Bremer, SW | 1 |
| Ye, KJ | 1 |
| Reddy, PV | 1 |
| Wu, GS | 1 |
| Wang, YA | 1 |
| Tainsky, MA | 1 |
| Ye, CJ | 1 |
| Michels, J | 1 |
| Geldart, T | 1 |
| Darby, A | 1 |
| Craddock, L | 1 |
| Iveson, A | 1 |
| Richardson, L | 1 |
| Iveson, T | 1 |
| Bochner, BH | 1 |
| Gårdmark, T | 1 |
| Jahnson, S | 2 |
| Wahlquist, R | 1 |
| Wijkström, H | 3 |
| Malmström, PU | 3 |
| Sugiura, M | 1 |
| Colby, KA | 1 |
| Mihm, MC | 1 |
| Zembowicz, A | 1 |
| Hartmann, JT | 2 |
| Pintoffl, JP | 1 |
| Quietzsch, D | 1 |
| Meisinger, I | 1 |
| Horger, M | 1 |
| Nehls, O | 1 |
| Bokemeyer, C | 2 |
| Königsrainer, A | 1 |
| Kanz, L | 2 |
| Isacoff, WH | 1 |
| Bendetti, JK | 1 |
| Barstis, JJ | 1 |
| Jazieh, AR | 1 |
| Macdonald, JS | 1 |
| Philip, PA | 1 |
| Ojea, A | 1 |
| Nogueira, JL | 1 |
| Flores, N | 1 |
| Gómez, JM | 1 |
| Molina, JR | 1 |
| Chantada, V | 1 |
| Camacho, JE | 1 |
| Piñeiro, LM | 1 |
| Rodríguez, RH | 1 |
| Isorna, S | 1 |
| Blas, M | 1 |
| Martínez-Piñeiro, JA | 1 |
| Madero, R | 1 |
| Nabhan, C | 1 |
| Ragam, A | 1 |
| Samuels, B | 1 |
| Milton, DT | 1 |
| Prasad, L | 1 |
| Hooberman, A | 1 |
| Hartsell, W | 1 |
| Anthony, A | 1 |
| Weisman, R | 1 |
| Bitran, JD | 1 |
| Ruutiainen, AT | 1 |
| Tuite, CM | 1 |
| Clark, TW | 2 |
| Mondschein, JI | 1 |
| Stavropoulos, SW | 1 |
| Trerotola, SO | 1 |
| Law, SK | 1 |
| Nguyen, AM | 1 |
| Coleman, AL | 1 |
| Caprioli, J | 1 |
| Vormittag, L | 1 |
| Kornek, GV | 2 |
| Gruhsmann, B | 1 |
| Lenauer, A | 1 |
| Föger, A | 1 |
| Depisch, D | 2 |
| Lang, F | 2 |
| Scheithauer, W | 2 |
| Biswas, MC | 1 |
| Shaw, C | 1 |
| Mandal, R | 1 |
| Islam, MN | 1 |
| Chakroborty, M | 1 |
| Karam, JA | 1 |
| Lotan, Y | 1 |
| Ashfaq, R | 1 |
| Sagalowsky, AI | 1 |
| Rolski, J | 1 |
| Zemełka, T | 1 |
| Jasiówka, M | 1 |
| Czyzewicz, G | 1 |
| Kojs-Pasińska, E | 1 |
| Shitara, K | 1 |
| Ikami, I | 1 |
| Munakata, M | 1 |
| Muto, O | 1 |
| Sakata, Y | 1 |
| Berghmans, T | 1 |
| Gourcerol, D | 1 |
| Lafitte, JJ | 1 |
| Kotsori, K | 1 |
| Paesmans, M | 1 |
| Scherpereel, A | 1 |
| Leclercq, N | 1 |
| Sculier, JP | 1 |
| Elias, D | 1 |
| Di Pietrantonio, D | 1 |
| Boulet, T | 1 |
| Honore, C | 1 |
| Bonnet, S | 1 |
| Goere, D | 1 |
| Kohneh-Shahri, N | 1 |
| Raynard, B | 1 |
| Sauter, ER | 1 |
| Langer, C | 1 |
| Coia, LR | 1 |
| Goldberg, M | 1 |
| Keller, SM | 1 |
| Lundholm, C | 2 |
| Norlén, BJ | 2 |
| Ekman, P | 1 |
| Lagerkvist, M | 1 |
| Lindeborg, T | 1 |
| Olsson, JL | 1 |
| Tveter, K | 1 |
| Westberg, R | 1 |
| Cakmakli, S | 1 |
| Ersöz, S | 1 |
| Karaayvaz, M | 1 |
| Arat, AR | 1 |
| Krege, S | 1 |
| Giani, G | 1 |
| Meyer, R | 1 |
| Otto, T | 1 |
| Rübben, H | 1 |
| Minervini, R | 1 |
| Felipetto, R | 1 |
| Viganò, L | 1 |
| Pampaloni, S | 1 |
| Fiorentini, L | 1 |
| Nohales Taurines, G | 1 |
| Cortadellas Angel, R | 1 |
| Arango Toro, O | 1 |
| Bielsa Gali, O | 1 |
| Gelabert Mas, A | 1 |
| Schwaibold, H | 1 |
| Klingenberger, HJ | 1 |
| Huland, H | 1 |
| Nuijts, RM | 1 |
| Vernimmen, RC | 1 |
| Webers, CA | 1 |
| Chung, HC | 1 |
| Cho, JY | 1 |
| Rha, SY | 1 |
| You, NC | 1 |
| Kim, JH | 1 |
| Noh, SH | 1 |
| Kim, CB | 1 |
| Min, JS | 1 |
| Kim, BS | 1 |
| Roh, JK | 1 |
| Ellis, P | 1 |
| Smith, I | 1 |
| Ashley, S | 2 |
| Walsh, G | 1 |
| Ebbs, S | 1 |
| Baum, M | 1 |
| Sacks, N | 1 |
| McKinna, J | 1 |
| Ayed, M | 1 |
| Ben Hassine, L | 1 |
| Ben Slama, R | 1 |
| Chelbi, N | 1 |
| Ghozzi, S | 1 |
| Drissi, H | 1 |
| Jemni, M | 1 |
| Chebil, M | 1 |
| Chopin, DK | 1 |
| Harstrick, A | 1 |
| Daikeler, T | 1 |
| Kollmannsberger, C | 1 |
| Müller, C | 1 |
| Seeber, S | 1 |
| Makris, A | 1 |
| Powles, TJ | 1 |
| Dowsett, M | 1 |
| Osborne, CK | 1 |
| Trott, PA | 1 |
| Fernando, IN | 1 |
| Ashley, SE | 1 |
| Ormerod, MG | 1 |
| Titley, JC | 1 |
| Gregory, RK | 1 |
| Allred, DC | 1 |
| Smits, G | 1 |
| Schaafsma, E | 1 |
| Kiemeney, L | 1 |
| Caris, C | 1 |
| Debruyne, F | 1 |
| Petrowsky, H | 1 |
| Heinrich, S | 1 |
| Staib-Sebler, E | 1 |
| Gog, C | 1 |
| Janshon, G | 1 |
| Lorenz, M | 1 |
| Wester, K | 1 |
| Busch, C | 1 |
| Ferraris, V | 1 |
| Serao, A | 1 |
| Buffa, G | 1 |
| Tanner, J | 1 |
| Dunst, J | 2 |
| Keuppens, FI | 1 |
| Whelan, P | 1 |
| Kliment, J | 1 |
| Robinson, MR | 1 |
| Rea, LA | 1 |
| Anderson, N | 1 |
| Lokich, J | 1 |
| Moore, C | 1 |
| Bern, M | 1 |
| Coco, F | 1 |
| Hagiwara, Y | 1 |
| Kitazawa, Y | 1 |
| Lamm, DL | 1 |
| Pagano, G | 1 |
| Korkina, LG | 1 |
| Inoue, Y | 1 |
| Oka, M | 1 |
| Ishii, H | 1 |
| Kimino, K | 1 |
| Kishikawa, M | 1 |
| Ito, T | 1 |
| Nakashima, M | 1 |
| Kohno, S | 1 |
| Smith, IE | 1 |
| O'Brien, ME | 1 |
| Talbot, DC | 1 |
| Nicolson, MC | 1 |
| Mansi, JL | 1 |
| Hickish, TF | 1 |
| Norton, A | 1 |
| Rajan, DK | 1 |
| Haskal, ZJ | 1 |
| Shlansky-Goldberg, RD | 1 |
| Freiman, DB | 1 |
| Chen, JS | 1 |
| Lin, YC | 1 |
| Jan, YY | 1 |
| Liau, CT | 1 |
| Sekine, H | 1 |
| Ohya, K | 1 |
| Kojima, SI | 1 |
| Igarashi, K | 1 |
| Fukui, I | 1 |
| Diestelhorst, A | 1 |
| Heynemann, H | 1 |
| Schrott, KM | 1 |
| Sauer, R | 1 |
| Brugger, S | 1 |
| Ullrich-Pur, H | 1 |
| Valencak, J | 1 |
| Raderer, M | 1 |
| Fiebiger, W | 1 |
| Kovats, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase II Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer[NCT00192049] | Phase 2 | 90 participants | Interventional | 2003-12-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder[NCT00191477] | Phase 3 | 355 participants (Actual) | Interventional | 2004-01-31 | Terminated (stopped due to The study was stopped early for futility reasons.) | ||
| A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT)[NCT02695771] | Phase 3 | 101 participants (Actual) | Interventional | 2016-04-19 | Completed | ||
| Effect of Intravesical B.C.G and Gemcitabine on Semen Quality and Testicular Volume in Patients With Non-muscle Invasive Bladder Cancer Patients[NCT05701332] | Phase 4 | 25 participants (Anticipated) | Interventional | 2023-04-01 | Not yet recruiting | ||
| A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions[NCT04172675] | Phase 2 | 107 participants (Actual) | Interventional | 2020-02-28 | Active, not recruiting | ||
| Prospective Cohort Study of Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy to Prevent Moderate-high Recurrence and Progression Risks of Muscle-invasive Bladder Cancer[NCT02716961] | 208 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | |||
| Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0[NCT01621217] | Phase 1 | 21 participants (Anticipated) | Interventional | 2012-06-30 | Completed | ||
| A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB)[NCT00384891] | Phase 3 | 190 participants (Actual) | Interventional | 2002-02-28 | Terminated (stopped due to slow accrual) | ||
| A Feasibility Study for Individualized Treatment of Patients With Advanced Pancreatic Cancer[NCT00276744] | Phase 2 | 249 participants (Actual) | Interventional | 2005-10-31 | Terminated (stopped due to Because there was no longer an active laboratory component to this study.) | ||
| Prospective Observational Study on Isolated Limb Perfusion of Melphalan in Treating Patients With Metastasis or Recidivism of Limb Melanoma or Sarcoma That Are Not Operable[NCT01920516] | 40 participants (Anticipated) | Observational | 2013-07-31 | Recruiting | |||
| Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma[NCT03664869] | Phase 3 | 300 participants (Anticipated) | Interventional | 2018-10-26 | Recruiting | ||
| Intravesical Electromotive Mitomycin for High Risk Urothelial Non-muscle Invasive Bladder Cancer After Intravesical Bacillus Calmette-Guérin Failure[NCT04311580] | Phase 2 | 52 participants (Actual) | Interventional | 2000-01-01 | Completed | ||
| Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.[NCT02259621] | Phase 2 | 45 participants (Anticipated) | Interventional | 2014-09-30 | Active, not recruiting | ||
| A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma[NCT00003018] | Phase 2 | 54 participants (Actual) | Interventional | 1997-09-30 | Completed | ||
| Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC[NCT03348969] | Phase 4 | 120 participants (Actual) | Interventional | 2017-11-01 | Active, not recruiting | ||
| Modified Trabeculectomy With an Extended Subscleral Tunnel Versus Conventional Trabeculectomy for Management of Primary Open Angle Glaucoma (POAG)[NCT03480711] | 40 participants (Actual) | Interventional | 2018-07-10 | Completed | |||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Defined as the time from study enrollment to the date of the first procedure confirming histopathological recurrence or disease progression or death from any cause. Recurrence-free survival (RFS) was censored at the date of the last follow-up visit for participants who were still alive and who had no recurrence/progression. (NCT00191477)
Timeframe: Surgery to recurrence or death (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
| Intervention | Months (Median) |
|---|---|
| Gemcitabine | 37.2 |
| Placebo | 40.2 |
RFS rate was estimated using Kaplan-Meier method. RFS was analyzed in different subgroups based on risk, disease status, and concomitant Bacillus Calmette-Guerin (BCG) instillations. Risk: Grading (G1,G2,G3) was performed according to American Joint Committee on Cancer Staging Criteria for Bladder Cancer. Newly diagnosed disease: Initial diagnosis at study entry. Recurrent disease: history of at least one superficial bladder tumor that was surgically treated and relapsed prior to study entry. With BCG: received at least one instillation of BCG during study. Without BCG: didn't receive BCG. (NCT00191477)
Timeframe: Surgery to recurrence or death (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
| Intervention | percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low Risk (G1/G2) - 12 Months (N=106, N=109) | Low Risk (G1/G2) - 24 Months (N=106, N=109) | High Risk (G3) - 12 Months (N=13, N=14) | High Risk (G3) - 24 Months (N=13, N=14) | Newly Diagnosed Disease - 12 Months (N=94, N=98) | Newly Diagnosed Disease - 24 Months (N=94, N=98) | Recurrent Disease - 12 Months (N=30, N=26) | Recurrent Disease - 24 Months (N=30, N=26) | With BCG - 12 Months (N=13, N=21) | With BCG - 24 Months (N=13, N=21) | Without BCG - 12 Months (N=111, N=103) | Without BCG - 24 Months (N=111, N=103) | |
| Gemcitabine | 78.5 | 63.9 | 66.7 | 57.1 | 79.3 | 65.4 | 72.2 | 59.5 | 61.5 | 49.2 | 79.9 | 65.8 |
| Placebo | 78.4 | 64.3 | 42.4 | 31.8 | 79.8 | 63.6 | 58.9 | 50.5 | 79.4 | 63.5 | 74.5 | 60.1 |
Because median time to recurrence was not reached, percentage of participants without event was estimated using Kaplan-Meier method. Time to recurrence was censored on date of death for patients who died, and on date of last visit for patients who were alive, without recurrence. (NCT00191477)
Timeframe: Surgery to recurrence (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Recurrence-Free at 12 Months | Recurrence-Free at 24 Months | |
| Gemcitabine | 78.4 | 66.3 |
| Placebo | 76.9 | 63.7 |
Tumor recurrence type (superficial, stage pTA or pT1; or muscle-invasive, stage≥pT2) was classified according to American Joint Committee on Cancer Staging Criteria for Bladder Cancer (AJCC Cancer Staging Manual, 6th edition). (NCT00191477)
Timeframe: Surgery to recurrence (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| No Tumor Recurrence | Superficial Tumor - Stage pTa or pT1 | Muscle-Invasive Tumor - Any Stage ≥pT2 | pTx - Tumor Cannot be Assessed | |
| Gemcitabine | 76 | 44 | 3 | 1 |
| Placebo | 78 | 45 | 1 | 0 |
The secondary endpoint for this study will be the number of subjects who did not experience dystrophic calcification or bladder calculi measured by the number of patients with Grade 3 through Grade 5 Adverse Events that are related to study arm, graded according to NCI CTCAE Version 4.03.Version 4.03 (NCT02695771)
Timeframe: Two years
| Intervention | Participants (Count of Participants) |
|---|---|
| Mitomycin C | 24 |
| Gemcitabine | 23 |
| No Intervention | 25 |
The NCI CTCAE Version 4.03 grades adverse events as follows: grade 3 include severe but non-life-threatening consequences that result in hospitalization and/or interventions, including elective radiologic or operative interventions; grade 4 events include life-threatening consequences, such as those requiring urgent reoperation; and grade 5 events result in treatment-related death. (NCT02695771)
Timeframe: Two years
| Intervention | Participants (Count of Participants) |
|---|---|
| Mitomycin C | 15 |
| Gemcitabine | 14 |
| No Intervention | 20 |
Percentage of patients survived at 6 months for patients whose tumors were xenografted and treated in the mouse when treated with the most active agent identified in that model (NCT00276744)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 | 53 |
18 reviews available for mitomycin and Disease Exacerbation
| Article | Year |
|---|---|
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2021 |
Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Carcinoma | 2017 |
[Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer].
Topics: Antibiotics, Antineoplastic; BCG Vaccine; Disease Progression; Humans; Hyperthermia, Induced; Mitomy | 2018 |
Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; BCG Vaccine; Disease Progression; Drug | 2018 |
Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoembolization, Th | 2014 |
Risk-adapted strategy for the kidney-sparing management of upper tract tumours.
Topics: Administration, Intravesical; Algorithms; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; | 2015 |
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitiona | 2016 |
Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocol | 2016 |
[Bacillus of Calmette-Guérin immunotherapy: which protocol?].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Clin | 2008 |
Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Disease Progres | 2009 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, | 2012 |
Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review.
Topics: Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; Carcinoma, Transitional Cell; Chemotherapy, Adjuva | 2012 |
Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carc | 2004 |
Mitomycin C primary trabeculectomy in primary glaucoma of white patients.
Topics: Antimetabolites; Cataract; Disease Progression; Glaucoma; Humans; Intraocular Pressure; Intraoperati | 1997 |
[Intravesical instillation in the treatment of superficial tumors of the bladder].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma; Carcinoma, Transi | 1998 |
Prospects for nutritional interventions in the clinical management of Fanconi anemia.
Topics: Anemia, Aplastic; Antibiotics, Antineoplastic; Cell Transformation, Neoplastic; Disease Progression; | 2000 |
A solitary bronchial papilloma with malignant changes.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, | 2001 |
Radiochemotherapy for T1G3 bladder cancer.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined | 2002 |
54 trials available for mitomycin and Disease Exacerbation
| Article | Year |
|---|---|
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherap | 2019 |
[Effectiveness of combined systemic and regional chemotherapy in treating patients with metastatic colorectal cancer after extrahepatic progression of the disease].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Reg | 2013 |
Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2014 |
Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy P | 2015 |
Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cetu | 2015 |
Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine | 2016 |
Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study.
Topics: Adult; Aged; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; | 2008 |
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2011 |
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
Topics: Animals; Deoxycytidine; Disease Progression; DNA Breaks, Double-Stranded; Drug Resistance, Neoplasm; | 2011 |
Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dis | 2011 |
Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable: implications for radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Chemoradiotherapy; Chronic Disease; D | 2011 |
Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, A | 2012 |
High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do | 2002 |
Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2002 |
Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2002 |
Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2003 |
IPM chemotherapy in cytokine refractory renal cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Ci | 2003 |
Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2003 |
Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Differe | 2003 |
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carboplatin; C | 2003 |
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Disease Progress | 2003 |
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Disease Progress | 2003 |
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Disease Progress | 2003 |
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma in Situ; Carcinoma, Transitional Cell; Disease Progress | 2003 |
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small | 2003 |
Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carcinoma | 2004 |
Phase II study of cisplatin and 5-fluorouracil (PF) and mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF) in patients with metastatic large bowel cancer: an Eastern Cooperative Oncology Group study (EST 1285).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Disease Progression; D | 2004 |
Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycyti | 2004 |
Mitomycin C, 5-fluorouracil and folinic acid (Mi-Fu-Fo) as salvage chemotherapy in breast cancer patients with liver metastases and impaired hepatic function: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2004 |
Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2005 |
Stop Flow in abdominal and pelvic cancer relapses.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2006 |
The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 2006 |
The combination of raltitrexed (Tomudex) and mitomycin-C in the treatment of advanced colorectal cancer--a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2006 |
Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineopl | 2007 |
Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do | 2007 |
Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dipy | 2007 |
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomyci
Topics: Administration, Intravesical; Aged; BCG Vaccine; Biopsy; Chemotherapy, Adjuvant; Cystectomy; Cystosc | 2007 |
Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for rectal carcinoma: a phase II study with long-term follow-up.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2007 |
Treatment of pterygium with conjunctival limbal autograft and mitomycin C--a comparative study.
Topics: Adult; Antibiotics, Antineoplastic; Conjunctiva; Disease Progression; Female; Humans; Male; Middle A | 2007 |
Mitomycin plus vinorelbine salvage chemotherapy in non-small cell lung cancer: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2008 |
Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytarabi | 1995 |
A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, A | 1996 |
A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine | 1996 |
Recurrences and progression of superficial bladder cancer following long-term intravesical prophylactic therapy with mitomycin C: 48-month follow-up.
Topics: Administration, Intravesical; Analysis of Variance; Antibiotic Prophylaxis; Antibiotics, Antineoplas | 1996 |
[Results of a prospective study of chemoprophylaxis with alternating mitomycin-C and BCG: complete response and recurrence and progression index].
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Combined Modality Therapy; Disease | 1996 |
Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy?
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 1997 |
Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Colorectal Neoplasms; Diarrhea; Disease Progressio | 1998 |
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 1997 |
Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Dise | 1998 |
5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Disease Progression; Follow-Up Stu | 1999 |
[Polychemotherapy versus monotherapy in metastatic breast carcinoma].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disea | 1999 |
Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial.
Topics: Antibiotics, Antineoplastic; Combined Modality Therapy; Disease Progression; Humans; Male; Mitomycin | 1999 |
A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dis | 1999 |
Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2001 |
Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bilia | 2001 |
Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder.
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma | 2001 |
Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2002 |
74 other studies available for mitomycin and Disease Exacerbation
| Article | Year |
|---|---|
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin.
Topics: Appendiceal Neoplasms; Bevacizumab; Capecitabine; Disease Progression; Humans; Hyperthermia, Induced | 2023 |
[Safety of Hyperthermic IntraVEsical Chemotherapy (HIVEC) for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vacci | 2020 |
Delta peritoneal cancer index (ΔPCI): A new dynamic prognostic parameter for survival in patients with colorectal peritoneal metastases.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma; Colorectal Neoplasms; Cytoreduction Surgical Procedure | 2020 |
Sequential intra-arterial infusion of 90Y-resin microspheres and mitomycin C in chemo refractory liver metastatic breast cancer patients: a single centre pilot study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Body Surface Area; Breast Neoplasms; Combined Modality The | 2020 |
E2F1 Promotes Progression of Bladder Cancer by Modulating RAD54L Involved in Homologous Recombination Repair.
Topics: Base Sequence; Cell Line, Tumor; Disease Progression; DNA Breaks, Double-Stranded; DNA Helicases; DN | 2020 |
Effectivity of intravescical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined | 2017 |
Effect of trabeculectomy on visual field progression in Japanese progressive normal-tension glaucoma with intraocular pressure < 15 mmHg.
Topics: Aged; Aged, 80 and over; Disease Progression; Female; Humans; Intraocular Pressure; Japan; Low Tensi | 2017 |
Palliation with a multimodality treatment including hypoxic pelvic perfusion for unresectable recurrent rectal cancer: outcomes based on a retrospective study.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Immunological; Cetuximab; Chemotherapy, Ca | 2018 |
Continuous saline bladder irrigation for two hours following transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer does not prevent recurrence or progression compared with intravesical Mitomycin-C.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modalit | 2018 |
Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Topics: Administration, Intravesical; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; | 2019 |
Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Disease Progression; Dox | 2019 |
Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2013 |
Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2013 |
Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Disease P | 2014 |
Induction of prophages by fluoroquinolones in Streptococcus pneumoniae: implications for emergence of resistance in genetically-related clones.
Topics: Blotting, Southern; Chronic Disease; Ciprofloxacin; Disease Progression; Drug Resistance, Bacterial; | 2014 |
The transformation of a nonfunctioning islet cell tumor of the pancreas into a proinsulinoma under conditions of lung metastasis.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Is | 2015 |
Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined | 2015 |
Predictive Factors for Time to Progression after Hyperthermic Mitomycin C Treatment for High-Risk Non-Muscle Invasive Urothelial Carcinoma of the Bladder: An Observational Cohort Study of 97 Patients.
Topics: Aged; Antibiotics, Antineoplastic; Biopsy; Carcinoma in Situ; Cohort Studies; Cystectomy; Cystoscopy | 2016 |
Hepatic arterial infusion chemotherapy using fluorouracil, epirubicin, and mitomycin C for patients with liver metastases from gastric cancer after treatment failure of systemic S-1 plus cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwellin | 2016 |
The Expanded Use of Percutaneous Resection for Upper Tract Urothelial Carcinoma: A 30-Year Comprehensive Experience.
Topics: Adjuvants, Immunologic; Adult; Age Factors; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BC | 2016 |
Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, | 2016 |
Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Agents; BCG Vaccine; Biomarkers; C-Reactive Protein; Ca | 2016 |
Spontaneous transformation of human granulosa cell tumours into an aggressive phenotype: a metastasis model cell line.
Topics: Animals; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Disease Progression; Female; Gr | 2008 |
Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Mo | 2009 |
Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoe | 2009 |
Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy.
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy | 2010 |
Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2009 |
Glaucoma surgery decreases the rates of localized and global visual field progression.
Topics: Algorithms; Disease Progression; Female; Glaucoma; Glaucoma Drainage Implants; Humans; Intraocular P | 2010 |
Target intraocular pressure for stability of visual field loss progression in normal-tension glaucoma.
Topics: Adult; Aged; Alkylating Agents; Disease Progression; Female; Follow-Up Studies; Humans; Intraocular | 2010 |
High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer.
Topics: Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Fluorouracil; Head and Neck N | 2010 |
Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation.
Topics: Adult; Antineoplastic Agents; Cell Differentiation; Cell Transformation, Neoplastic; Disease Progres | 2010 |
Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemot | 2010 |
Superficial bladder tumours: recurrence and progression.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Biopsy; Carcinoma, Transitional Cell; C | 2011 |
RNA interference-mediated vascular endothelial growth factor-C reduction suppresses malignant progression and enhances mitomycin C sensitivity of bladder cancer T24 cells.
Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Disease Progression | 2012 |
Progression of normal tension glaucoma in Kearns-Sayre syndrome over 10 years.
Topics: Adult; Alkylating Agents; Corneal Endothelial Cell Loss; Disease Progression; Female; Follow-Up Stud | 2012 |
Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2012 |
Progression of primary acquired melanosis with atypia during pregnancy.
Topics: Administration, Topical; Adult; Antibiotics, Antineoplastic; Conjunctival Diseases; Disease Progress | 2012 |
Is there still a role for mitomycin-based combination chemotherapy in treating patients with nonsmall cell lung cancer? A single institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell | 2013 |
Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemoemboliz | 2012 |
Nonselective transarterial chemoperfusion: a palliative treatment for malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Femal | 2013 |
[Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid].
Topics: Aged; Aged, 80 and over; Autoimmune Diseases; Disease Progression; Drug Evaluation; Drug Therapy, Co | 2002 |
Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2002 |
Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxy | 2003 |
Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 2003 |
T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic | 2004 |
Chemoembolization of liver metastasis from breast carcinoma.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcin | 2004 |
Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer.
Topics: Aged; Alternative Splicing; Antineoplastic Agents, Alkylating; BCG Vaccine; Carcinoma in Situ; Carci | 2004 |
Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Disease P | 2004 |
C-MYB, serum P-53M, genetic instability, labeling index and endoscopic findings in patients with adenoma or colorectal cancer.
Topics: Adenoma; Biomarkers, Tumor; Chromosome Aberrations; Colorectal Neoplasms; Disease Progression; DNA; | 2004 |
Treatment of unresectable lung metastases with transpulmonary chemoembolization: preliminary experience.
Topics: Adult; Aged; Aged, 80 and over; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; | 2005 |
Prevention of posterior glottic stenosis by mitomycin C.
Topics: Animals; Constriction, Pathologic; Disease Progression; Glottis; Granulation Tissue; Laryngeal Disea | 2005 |
Electromotive drug delivery and bladder cancer.
Topics: Antibiotics, Antineoplastic; Clinical Trials as Topic; Disease Progression; Electric Stimulation The | 2006 |
Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineo | 2006 |
Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal N | 2006 |
Stochastic cancer progression driven by non-clonal chromosome aberrations.
Topics: Animals; Cell Line; Cell Line, Transformed; Cell Line, Tumor; Cell Transformation, Viral; Cells, Cul | 2006 |
Intravesical bacillus Calmette-Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Clin | 2006 |
Low-risk and high-risk histologic features in conjunctival primary acquired melanosis with atypia: Clinicopathologic analysis of 29 cases.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Cell Nucleolus; Cell Nucleus; Chemother | 2007 |
Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendo | 2007 |
Severe loss of central vision in patients with advanced glaucoma undergoing trabeculectomy.
Topics: Adult; Aged; Aged, 80 and over; Alkylating Agents; Disease Progression; Female; Follow-Up Studies; G | 2007 |
UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 2007 |
Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; BCG Vaccine; Carcinoma, Transitio | 2007 |
[Chemotherapy of advanced non small cell lung cancer: effect on survival and symptoms affecting quality of life].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2007 |
Hepatic arterial infusion of mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrah | 2008 |
"Natural history" of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Drainage; | 2009 |
A prospective evaluation of the treatment of primary or metastatic liver carcinoma with hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1996 |
Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplasti | 1997 |
Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Ne | 1998 |
[Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].
Topics: Actuarial Analysis; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antin | 1998 |
[Isolated hypoxic perfusion with mitomycin C confers no benefit for patients with advanced pancreatic carcinoma].
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Cell Hypoxia; Disease Progression; Female; Humans | 1998 |
[Long-term effects on recurrence and mortality in superficial urothelioma of the bladder treated with endovesical chemotherapy].
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitiona | 1999 |
The effect of mitomycin C trabeculectomy on the progression of visual field defect in normal-tension glaucoma.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Disease Progression; Female; Glaucoma, Open-Angle; Humans; Intr | 2000 |
Re: bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 AND TIS)
Topics: Antibiotics, Antineoplastic; BCG Vaccine; Disease Progression; Humans; Mitomycin; Neoplasm Staging; | 2000 |
Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization.
Topics: Chemoembolization, Therapeutic; Cisplatin; Disease Progression; Doxorubicin; Ethiodized Oil; Female; | 2001 |
Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients.
Topics: Adenocarcinoma, Mucinous; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; | 2001 |